Company Profile
Updated: 28-OCT-09Octapharma AG
Non-Quoted Public Company
Seidenstrasse 2, Lachen, CH-8853, Switzerland
()41 055 451 21 21, 41 055 451 21 10 fax, http://www.octapharma.ch
Primary SIC: Biological Products Except Diagnostic, Primary NAICS: Biological Product (except Diagnostic) Manufacturing
Description: Manufacturing: Development, production and distribution of virus-inactivated, high-purity, human plasma derivatives
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Research and Markets Offers Report: Blood Banking and Blood Products - Global Market Perspective
Wireless News; 12/1/2009; 891 words; ...Agreement - Haemonetics Signs Contract with Octapharma - Immucor Obtains Clearance from FDA for...New York Blood Center (USA) - VITA 34 AG (Germany) - Beckman Coulter, Inc...Fractionnement et des Biotechnologies (France) - Octapharma (Switzerland) - Sanquin (The Netherlands...
Research and Markets Adds Report: Blood Banking and Blood Products - Global Market Perspective.
Health & Beauty Close-Up; 11/25/2009; 1088 words; ...Agreement - Haemonetics Signs Contract with Octapharma - Immucor Obtains Clearance from FDA for...New York Blood Center (USA) - VITA 34 AG (Germany) - Beckman Coulter, Inc...Fractionnement et des Biotechnologies (France) - Octapharma (Switzerland) - Sanquin (The Netherlands...
ProMetic Reports Its Third Quarter 2009 Highlights and Financial Results.(Financial report)
Marketwire Canada; 11/13/2009; 2581 words; ...revenue prepayment against an existing supply contract with Octapharma AG ("Octapharma"), which brings the total prepaid to date to pounds sterling...announcement had a direct and positive impact to ProMetic and Octapharma. OctaplasLG
Other News To Note.
BioWorld International; 11/4/2009; 2701 words; ...entered a license agreement with Octapharma AG, of Lachen, Switzerland, to...recombinant Factor IX (FIX). Octapharma produces FIX for the treatment...hemophilia B. Under the FIX agreement Octapharma will have license to use BAC...
Swiss bid to build blood plant stalled.
Australasian Business Intelligence; 11/1/2009; 352 words; ...Government response to its plans for a blood plant. Octapharma Australia offered to build a $A400 million...Government. Publication Date: 2 November 2009 OCTAPHARMA AUSTRALIA PTY LTD OCTAPHARMA AG CSL LIMITED - ASX CSL AUSTRALIA. DEPT OF HEALTH...
Recent News Articles
- Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market.(Financial report)
Biotech Week - October 21, 2009 - OCTAPHARMA AG ANNOUNCES Q2 ESULTS AND MID TERM OUTLOOK OF MARKET.
AsiaPulse News - October 05, 2009 - Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market.
PR Newswire - October 02, 2009 - Octapharma AG Announces First-Ever Research Grants Program, Demonstrating Commitment to Cutting-Edge Clinical Research.
Business Wire - March 30, 2009
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning